[HTML][HTML] Mechanisms of action of fluvoxamine for COVID-19: a historical review
Y Hashimoto, T Suzuki, K Hashimoto - Molecular psychiatry, 2022 - nature.com
The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) accelerates the discovery of …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) accelerates the discovery of …
[HTML][HTML] Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19
Mapping non-canonical cellular pathways affected by approved medications can accelerate
drug repurposing efforts, which are crucial in situations with a global impact such as the …
drug repurposing efforts, which are crucial in situations with a global impact such as the …
Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help fight COVID-19 and save lives?
Y Pashaei - Journal of Clinical Neuroscience, 2021 - Elsevier
The current 2019 novel coronavirus disease (COVID-19), an emerging infectious disease, is
undoubtedly the most challenging pandemic in the 21st century. A total of 92,977,768 …
undoubtedly the most challenging pandemic in the 21st century. A total of 92,977,768 …
[HTML][HTML] Fluvoxamine for the early treatment of SARS-CoV-2 infection: a review of current evidence
SARS-CoV-2 infection causes COVID-19, which frequently leads to clinical deterioration
and/or long-lasting morbidity. Academic and governmental experts throughout the USA met …
and/or long-lasting morbidity. Academic and governmental experts throughout the USA met …
Antidepressants for COVID-19: A systematic review
Objective To systematically examine the efficacy and safety of antidepressants for the
treatment of coronavirus disease 2019 (COVID-19). Methods A systematic search was …
treatment of coronavirus disease 2019 (COVID-19). Methods A systematic search was …
[HTML][HTML] Fluvoxamine: a review of its mechanism of action and its role in COVID-19
Fluvoxamine is a well-tolerated, widely available, inexpensive selective serotonin reuptake
inhibitor that has been shown in a small, double-blind, placebo-controlled, randomized …
inhibitor that has been shown in a small, double-blind, placebo-controlled, randomized …
[HTML][HTML] Antidepressant and antipsychotic drugs reduce viral infection by SARS-CoV-2 and fluoxetine shows antiviral activity against the novel variants in vitro
Repurposing of currently available drugs is a valuable strategy to tackle the consequences
of COVID-19. Recently, several studies have investigated the effect of psychoactive drugs on …
of COVID-19. Recently, several studies have investigated the effect of psychoactive drugs on …
[HTML][HTML] Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms
We read with great interest the correspondence letters of Salles et al.[1] and Stip et al.[2],
following our multicenter observational retrospective study that showed a substantial …
following our multicenter observational retrospective study that showed a substantial …
[HTML][HTML] Fluoxetine can inhibit SARS-CoV-2 in vitro
A Dechaumes, MP Nekoua, S Belouzard, F Sane… - Microorganisms, 2021 - mdpi.com
An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) resulted in
the coronavirus disease pandemic, drastically affecting global health and economy. Though …
the coronavirus disease pandemic, drastically affecting global health and economy. Though …
Do the selective serotonin reuptake inhibitor antidepressants fluoxetine and fluvoxamine reduce mortality among patients with COVID-19?
N Hoertel - JAMA network open, 2021 - jamanetwork.com
In a large, multicenter, retrospective cohort study of 83 584 patients with laboratory-
confirmed COVID-19 who had an emergency department or urgent care visit or were …
confirmed COVID-19 who had an emergency department or urgent care visit or were …